Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

Matthew R. Janes, Jingchuan Zhang, Lian‐Sheng Li, +31

Cell

Kras Mutant CancersMedicineAnti-cancer AgentCancer BiologyRadiation Oncology +4

Discovery and SAR of 5-(3-Chlorophenylamino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer

Fabrice Pierre, Peter Chua, Sean O’Brien, +22

Journal of Medicinal Chemistry

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics

Mustapha Haddach, Michael K. Schwaebe, Jerome Michaux, +16

ACS Medicinal Chemistry Letters

EngineeringRna PolMolecular BiologyPharmaceutical ChemistryNucleic Acid Biomarkers +15

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer

Fabrice Pierre, Peter Chua, Sean O’Brien, +21

Molecular and Cellular Biochemistry

MedicineCancer GrowthImmune Checkpoint InhibitorAnti-cancer AgentPre-clinical Characterization +6

Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor

Mustapha Haddach, Jerome Michaux, Michael K. Schwaebe, +19

ACS Medicinal Chemistry Letters

Pim KinasesPharmacotherapyA PotentCompound 13Tumor Biology +16

Novel potent pyrimido[4,5-c]quinoline inhibitors of protein kinase CK2: SAR and preliminary assessment of their analgesic and anti-viral properties

Fabrice Pierre, Sean O’Brien, Mustapha Haddach, +11

Bioorganic & Medicinal Chemistry Letters

BiochemistryProtein Kinase Ck2MedicineNatural SciencesAnti-viral Properties +9

Dynamic turnover of arabinogalactan proteins in cultured Arabidopsis cells

Levan Darjania, Nobutoshi Ichise, Satoko Ichikawa, +3

Plant Physiology and Biochemistry

Plant Molecular BiologyBiosynthesisEngineeringBiochemistryDynamic Turnover +1

Abstract 5168: KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors

Francis Burrows, Linda Kessler, Jeffrey Chen, +15

Cancer Research

Ko-947 Blocks ErkBraf/ras MutationsCancer BiologyTumor BiologyOncology +14

Abstract A171: A potent and selective PI3K inhibitor, INK1117, targets human cancers harboring oncogenic PIK3CA mutations.

Katti Jessen, Linda Kessler, Jeff Kucharski, +16

Molecular Cancer Therapeutics

Cancer BiologyTumor BiologySelective Pi3k InhibitorOncologyCancer Cell Biology +14

Abstract 3753: Potent anti-tumor activity of mTOR kinase inhibitor in combination with anti-angiogenic agents in preclinical models of renal cell cancer

Shunyou Wang, Lucy Lan, Mathew Janes, +15

Cancer Research

Abstract 3753UrologyMtor Kinase InhibitorsMedicineTumor Growth +11